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ABSTRACT 
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The INK4A-ARF locus encodes two tumor suppressors; p16 and p19
Arf
, both of which restrain 
cell growth by regulating the functions of Retinoblastoma (Rb) and p53 respectively. Throughout 
development, p19
Arf
 is kept at minimal levels, but under conditions of oncogenic stress, p19
Arf
 
expression is induced and its tumor suppressive activities are mediated through the stabilization 
of p53 or in a p53-independent manner. Introducing a point mutation (L46D) into the conserved 
hydrophobic domain (37-51) in p19
Arf
 annulled ARF/CtBP2 interaction and mediated cell 
xi 
 
 
 
survival by rendering cells irresponsive to apoptosis. In vivo analysis on the percentage of 
lymphoma free survivals in ARFL46D/L46D mice indicated that disrupting ARF/CtBP2 binding 
resulted in a tumor spectrum similar to that in ARF-null mice. In this study, we characterized the 
functions of the hydrophobic domain of ARF in MEF cells under genotoxic stress, ultra-violet 
irradiation and oncogene activation. We demonstrated that cells bearing the mutation showed 
decreased responsiveness to H-RasV12 induced senescence consistent with p21 deficiency. We 
speculate that the deficit in p21 expression is possibly caused by CtBP2 repressive and oncogene 
-like properties.  
 
 
1 
 
 
 
CHAPTER I 
INTRODUCTION 
 
 
I.1 Cancer: progression or suppression 
Carcinogenesis is a process that develops through a series of insults at the genetic and 
epigenetic levels ultimately leading to the loss of homeostasis and control of cell division. 
Axiomatic requirements of cancer cells include: 1) capacity to proliferate irrespective of 
exogenous mitogens; refractoriness to growth inhibitory signals; resistance to apoptosis; 
unrestricted proliferation potential; capacity to recruit vasculature; ability to invade surrounding 
tissue and metastasize; reprogramming of energy metabolism and evading immune destruction 
(Hanahan & Weinberg, 2011). At the molecular level, interplay among tumor suppressors and 
proto-oncogenes regulates the progression of the cells throughout the cell cycle. In cases where 
tumor suppressor genes fail to function increase the risks of developing cancer. In this context, 
mutations in p53 and the INK4A/ARF locus are the two most common genetic lesions identified 
in human tumors (Ruas & Peters, 1998). A previous study on 37 patients with Adult T-cell 
leukemia (ATLL) identified inactivation deletion mutations in p14
ARF
 associated with over 35% 
of the cases with poor prognosis  and therefore reflecting the significance of the INK4A/ARF 
locus in tumor suppression and homeostasis. 
Data from murine models with targeted deletions of p16
INK4a
 and p19
Arf
 suggests that 
mice with either deletion are prone to tumor formation and animals with both deletions are more 
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severely affected with histiocytic lymphoma similar to human Non-Hodgkin Lymphoma (NHL) 
comprising up to 90% of tumors (Sharpless, 2005). The tumor spectrum of ARF-null mice was 
similar to p53 knockout mice with the highest frequency of tumors being lymphocytic lymphoma 
of the thymus and/or lymph nodes (Table1). Although similar, p53 null mice developed T- cell 
lymphomas at a frequency of 70 % as opposed to small lymphocytic lymphoma arising in ARF-
null mice at a lower frequency and longer mean latency of 38 weeks (Sharpless, 2005). Both 
tumor suppressor deletions also led to sarcoma formation as well (Ozenne, Eymin, Brambilla, & 
Gazzeri, 2010). Mitogen activated tumorigenesis revealed increased incidence in the frequency 
of all tumors in the various knockout mice models with additional tumor types (lung 
adenocarcinoma) now evident (Wang, Zhang, Kastens, Lubet, & You, 2003). 
 
I.2 The INK4B - INK4A/ARF Locus 
The INK4B-ARF-INK4A locus encodes two known tumor suppressors of the INK4 family 
proteins p15
INK4b
 and p16
INK4a
 respectively. The INK4A/ARF locus is unique in mammals in the 
sense that it encodes two structurally unrelated proteins CDKN2A (p16
INK4a
) and p19
Arf
 in mice / 
p14
ARF
 in human, due to overlapping but frame shifted coding sequences (Gil & Peters, 2006). 
The locus is roughly 25Kb long, shorter than most mammalian loci, and consists of 4 exons (1α, 
1 β, exon2 and exon3). 
Transcription initiation proceeds at two distinct promoters upstream of exons 1 α and 1 β with 
13Kb of intervening sequences separating the two exons in the mouse genome (Sherr, 1998). 
Both exons 1 α and 1 β share the same splice acceptor site with exon 2(Quelle, Zindy, Ashmun, 
& Sherr, 1995). Transcripts originating from exon 1 α lead to p16INK4a gene product whereas 
transcripts initiating from the promoter sequence upstream of exon 1β produces alternative 
reading frame transcripts (p19
Arf
). Although exon 2 is fully transcribed in either gene product, 
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p16
INK4a
 and p19
Arf
/p14
ARF
 share no homologous domains between their amino acid sequences 
(Figure 1). This variation is due to the initiation of transcription from overlapping reading frames 
and alternative splicing.  
 
 
 
 
 
 
 
 
             
Figure 1. The INK4A-ARF locus. Arrows indicate transcription initiation sites. Segments 
indicate the genomic region(s) targeted to establish the required knock-outs. (Nature Reviews)  
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I.2.1 Evolutionary significance of INK4A/ARF locus 
The INK4A/ARF is an unusual dual coding-region located on chromosome 9p21 in 
humans and on chromosome 4 in mice. From an evolutionary point of view, mammalian 
genomes are more complex than their marine ancestors. Genome analysis of Zebra fish and Fugu 
(Japanese puffer fish) showed that the INK4B-INK4A and INK4C-INK4D loci produce single 
p15/p16 and p18/p19 like member proteins. There is no evidence that ARF-like ortholog exists 
in the genome or the epigenome of Zebrafish and Fugu leading to the suggestion that ARF has 
been incorporated into the genome of vertebrates after a duplication event which ultimately led 
to splitting the INK4B-INK4A and INK4C-INK4D loci into 4 distinct coding regions (Sharpless, 
2005). So why do vertebrates require an additional INK4 protein? Is there an evolutionary 
advantage in duplicating the INK4 loci and thereby introducing ARF into the genomic DNA? Is 
it economical for cells to initiate transcription from two separate promoters and therefore fuel 
more biological processes? Evidence from functional analysis in human and mice, document that 
the transition from water to land resulted in a shift in the potency of tumors, and thus provided 
more demand for tumor suppressors (Sharpless, 2005).  
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       Table 1. Tumor profile in several INK4A/ARF knock-out mouse models 
 
 
 
 
 
 
 
 
Genotype Tumor spectrum and Penetrance 
Spontaneous 
tumor mean 
latency  in 
weeks 
MEF 
properties 
 
Spontaneous 
Mitogen Induced                       
(DMBA) 
  
p53 -/- 
Lymphoma 77%; 
Sarcoma23% NA 20 Immortal 
ARF -/- 
Small 
Lymphocytic  
Lymphoma 37%; 
Sarcoma 33%  
Small Lymph. 
Lymphoma 60% 
Lung carcinoma 
40% 38 
Immortal, 
Transformed 
by H-Ras V12 
INK4A -/- 
Sarcoma 52%  
Histiocytic 
Lymphoma 18% 
Small 
Lymphocytic 
Lymphoma 39% 
Lung carcinoma 
17% 68 
Resemble 
Wild type; 
Undergo 
senescence 
INK4A/ARF-/- 
Histiocytic 
Lymphoma 90%    
Sarcoma 10% NA 34 
Immortal; 
Transformed 
by H-Ras V12  
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I.2.2 Transcriptional regulation of the INK4A/ARF locus 
Regulation of transcription from the promoters of INK4A and ARF is kept under tight 
control in normal proliferating cells. In particular, early passage mouse and human embryonic 
cells show undetectable amounts of Arf mRNA and protein (Lowe & Sherr, 2003). Continuous 
passaging of mouse and human embryonic fibroblasts led to the buildup of both p16 and p19 
with supporting evidence that the latter is more involved in protecting MEF cells from 
hyperproliferative/oncogenic signaling (Gil & Peters, 2006). As mentioned previously knockout 
mice for INK4A and ARF are more prone to tumor formation compared to INK4A or ARF 
knockout mice. The most accepted paradigm in characterizing the significance of each of the two 
tumor suppressors is that p16
INK4a
 is more critical in inducing senescence and tumor suppression 
in human embryonic fibroblasts, whereas p19
Arf
 is primarily the key player in these functions in 
mouse embryonic fibroblasts with compelling evidence from knock-out mouse models(Sharpless 
et al., 2001) . MEF cells from ARF-null mice bypassed spontaneous induced senescence in 
culture and rendered ARF-null cells immortal (Gil & Peters, 2006).  
Several oncogenic activators have been identified in terms of their association with 
transcription initiation from the ARF promoter either directly or indirectly. For instance, mutant 
forms of Ras in MEF cells lead to ARF induced senescence by increasing the expression of ARF 
from its promoter indirectly through the activation of DMP1(cyclin D binding Myb-like protein) 
transcription factor that was found through chromatin immunoprecipitation studies bound to 
nonameric consensus sequences CCCG(G/T)ATG(T/C) in the ARF promoter dislodging 
repression caused by E2F-3b complex(Sreeramaneni, Chaudhry, McMahon, Sherr, & Inoue, 
2005). Previous studies showed that the oncogenic signaling through H-Ras V12 activates DMP1 
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through the RAF-MEK-ERK pathway, which results in the activation of transcription factors that 
belong to the Fos and Jun family, and their subsequent binding to 5’ leader sequence responsive 
elements in the mouse DMP1 promoter resulting in an increase in the DMP1 pool in the nucleus 
(Sreeramaneni et al., 2005).  
Activation of transcription from the ARF promoter by DMP1 is a multistep process. The 
ARF promoter contains DMP1 and E2F binding sites. In normal unstressed cells, the E2F3b 
complex represses transcription of ARF (Asp, Acosta-Alvear, Tsikitis, van Oevelen, & Dynlacht, 
2009) by binding polycomb protein Bmi-1 and thus establishing transcriptionally silent 
chromatin. In the presence of hyperproliferative/oncogenic stress caused by H-Ras V12, cyclin D 
is activated and assembles with CDK4, enabling the dissociation of E2F1,2 from Retinoblastoma 
(Rb) and thereby allowing DMP1 induced transcription from  the ARF promoter (Sreeramaneni 
et al., 2005). In addition to the indirect transcriptional activation by H-Ras, transcription of ARF 
is mediated indirectly through other oncogenic proteins such as c-Myc, which in contrast to H-
Ras, results in p53-independent apoptosis as opposed to premature senescence (Boone, Qi, Li, & 
Hann, 2011). Twist and Dermo two well-characterized transcriptional repressors of the ARF 
promoter, were identified in a screen for proteins that bypass Myc induced apoptosis (Table2). 
Moreover, INK4A/ARF-null mouse models compensated for the loss of Bmi-1 polycomb 
repressor protein, which is evidence that INK4A and ARF are downstream targets of Bmi-1 
mediated transcriptional repression, and ARF is required to be expressed at least minimal levels 
for proper mouse development (Sharpless & DePinho, 1999). 
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Table 2. List of activators and repressors of the INK4A/ARF locus 
Activator Repressor 
DMP1 pRb 
E2F1,E2F2,E2F3 p53 
Ras Twist 
Myc TBX2,TBX3 
c-Jun ATM 
ABL E2F3b 
B-catenin JUND 
 
 
I.2.3 The INK4A/ARF locus in tumor suppression and cell cycle regulation 
Several lines of evidence suggest that the INK4A/ARF gene products p16
INK4a
 and ARF 
(p19 in mouse, p14 in human) are potent tumor suppressors and involved in cell cycle regulation. 
Mutations targeting INK4A/ARF locus are common and are second in frequency to TP53 
mutations in humans. Previous studies showed that homozygous and hemizygous deletions and 
epigenetic silencing of the p14
ARF
 promoter were detected in 41% of individuals out of 100 
surveyed patients diagnosed with primary breast carcinomas (Yi et al., 2004). Although p16 and 
p19 are encoded from the same locus, their expression is not the same in all tissues in human and 
mice. In a separate study, epigenetic silencing of p14
ARF
 promoter was documented in human 
colorectal cancer cells (Esteller et al., 2001). Interestingly, in 14 out of 22 NSCLC with p16 
mutations, p16 inactivation also resulted in p14
ARF
 inactivation through homozygous deletions 
extending into the INK4A/ARF along with two point mutations in exon 2 (Sanchez-Cespedes et 
al., 1999). Recently, it has been shown that H3K27Me3, which is an indicator for transcriptional 
silencing was strongly associated with the ARF locus in T- ALL leukemia- initiating cells {{67 
Volanakis,E.J. 2012}}. So far, no point mutations in exon 1 β have been reported. As mentioned 
previously, the INK4A locus encodes a CDK inhibitor known as p16
INK4a
. The original paradigm 
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in defining the functional differences between p19
Arf
 and p16
INK4a
 was determined through 
studying changes in protein expression in human cells undergoing replicative or premature 
senescence and their association with cellular immortalization either due to cell culture shock or 
upon ectopic stress. These studies, led to the identification of retinoblastoma protein (Rb) and 
p53 as direct downstream targets of p16 and p19 respectively (Ruas & Peters, 1998). Based on 
that, two pathways have been identified with which signaling through either p16 or p19 takes 
place. Convincing evidence suggests that ARF is the primary tumor suppressor in mice encoded 
by the INK4A/ARF locus, since p16
INK4a
-null MEFs are phenotypically undistinguishable from 
wild type primary mouse embryonic fibroblasts and are not sensitive to H-Ras V12 
transformation (Ozenne et al., 2010). The p16
INK4a 
- Rb pathway functions in tumor suppression 
by regulating cell proliferation through the repression of the genes which are responsible for the 
progression through the G1 phase of the cell cycle and entry into the S phase. Depending on the 
phosphorylation state of retinoblastoma, Rb binds E2F and inhibits the transcription of cell cycle 
proteins in its hypophosphorylated state by recruiting histone deacetylases thus making the 
promoters less accessible for transcription initiation. The phosphorylation status of Rb is 
regulated by cyclin dependent kinases 4 and 6 (CDK4,6), which themselves are activated in 
response to increasing levels of cyclin D1, and kept under tight regulation by the cdk inhibitory 
functions of p16INK4A (Sherr & McCormick, 2002). Mitogenic signaling through Ras/MAP 
kinase pathway, induces the transcription of D-type cyclins that form complexes with CDK4 and 
CDK6, thereby releasing E2F by phosphorylating Rb at Ser 795 and Ser807/811 phosphorylation 
sites, rendering it inactive and inducing the cells into entering the S-phase(Knudsen & Wang, 
1996). Signaling through Ras-MAPK also results in inducing transcription of INK4A and ARF.  
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On the other hand, ARF functions in tumor suppression primarily through the p53 
pathway. ARF is a nucleolar protein that binds nucleophosmin/B23 and localizes to the nucleolus 
to form a high molecular weight stable complex with a half-life time from 1 to 8 hours (Ozenne 
et al., 2010). It is a basic protein with more than 20% Arginine residues (pI >12) and possesses 
hydrophobic properties. p14
ARF
 is 132aa long, whereas p19
Arf
 is 169aa, with almost 50% 
sequence homology between the human and mouse orthologs. The first 62 amino acids in 
p19ARF are encoded by exon 1 β. Amino acids 26-37 encode a nucleolar localization sequence 
(NoLS) and cooperative MDM2 binding sites include amino acids 1-14 and 26-37    
(Korgaonkar, Zhao, Modestou, & Quelle, 2002). p19
Arf
 has only one lysine and there are none in 
p14
ARF
 and no known secondary structures have been identified, unless associated with other 
molecules in complexes required for neutralizing its high basic properties (Chung, Wadhawan, 
Szklarczyk, Pond, & Nekrutenko, 2007) (Table 3).  
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    Table 3. List of ARF-interacting proteins and their function(s) 
Protein Function 
ARF-BP1 HECT- containing E3 ubiquitin ligase 
E2F1  Transcription factor required for DNA 
synthesis 
Myc 
 
Transcription factor required for the 
transactivation and transrepression of 
several genes 
CtBP1,CtBP2 Anti-apoptotic transcription co-repressors 
PARF Putative GTP-binding protein 
Nucleophosmin B23 A nucleolar phosphoprotein required for 
rRNA synthesis  
UBC9 An E2 conjugating enzyme required for 
sumoylation 
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Two internal methionine residues Met 45 and Met 48 have been identified in mouse and 
human ARF, respectively, and translation initiation from these two methionines results in shorter 
ARF molecules known as smARF that when overexpressed localize to the mitochondria 
(Balaburski, Hontz, & Murphy, 2010) since they lack nucleolar localizing sequences (NoLS) 
encoded by exon 1 β. This localization is a signal for autophagy, which is a mechanism with 
which cell die in response to low nutrients due to organelle autodigestion. However, the 
mechanism which smARF induces autophagy is still unclear.  
ARF/p53 knockout mice have a greater risk of developing malignant tumors than an ARF 
or p53 single knockout. This suggests that ARF functions in tumor suppression through p53 
dependent and independent mechanisms (Kawagishi et al., 2010). p53 dependent functions of 
ARF ultimately lead to the activation of p53 through the ARF-MDM2-p53 pathway resulting in 
cell cycle arrest, senescence or apoptosis. Overexpression of p19
Arf
 ectopically, or upon 
hyperproliferative signals, results in cell cycle arrest either at G1 or G2 phases (Quelle et al., 
1995). This primarily occurs due to the ability of full length ARF to neutralize the E3 ubiquitin 
ligase activity of the p53 antagonist murine double minute 2 (MDM2). After binding MDM2, 
ARF sequesters MDM2 into the nucleolus therefore inhibiting MDM2 mediated ubiquitination 
and proteasomal degradation of p53, thus rendering p53 more stable and active. p53 then induces 
cell cycle arrest by transcriptionally activating p53 downstream target genes with anti-
proliferative functions such as p21CIP, which in turn inhibits the activity of CDK2 keeping 
retinoblastoma in a hypophosphorylated active state (Serrano, 2000).  
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I.2.4 p53- independent functions of ARF 
As mentioned previously, ARF functions in tumor suppression in a p53 independent 
pathway, and debate on how ARF exerts its inhibitory control independently of p53 has not been 
fully resolved.  Yeast two-hybrid system and immunoprecipitation studies showed that ARF 
directly binds a broad range of protein molecules involved in cell cycle progression (Figure2). In 
particular, ARF binds and represses the functions of Myc, E2F1, NF-ĸB, cyclin G1, WRN and 
B23 (Sherr et al., 2005) by sequestering them into the nucleolus and/or by disabling their binding 
to co-activator molecules. B23 is a key player in ribosomal biogenesis and shuttles between the 
nucleolus, nucleoplasm and the cytoplasm (Korgaonkar et al., 2005). Therefore, one way with 
which ARF functions as a tumor suppressor, is through impeding the translocation of B23 out of 
the nucleolus and hindering rRNA transcription and processing (Sherr, 2006). ARF has also been 
found to play an important role in sumoylation by associating with UBC9. This interaction is 
believed to enhance the transfer of sumo group to ARF binding proteins thereby triggering their 
proteasomal degradation (Sherr, 2006). Although ARF expression is not induced by DNA 
damaging agents, overexpression of p14
ARF
 leads to activation of ATR/CHK1 dependent NF-kB 
phosphorylation which in turn leads to TNFα dependent apoptosis (Ozenne et al., 2010). 
Recently, the anti-apoptotic transcriptional co-repressor CtBP2 has been identified to bind  the 
conserved hydrophobic domain of ARF at amino acid residues (46-51), and ARF targets this 
oncogenic co-repressor for proteasomal degradation in cells also exposed to stress such as UV 
(Paliwal et al., 2006) (Figure2). Moreover autophagy induced death upon smARF over-
expression is considered a p53-independent function of ARF (Sherr, 2006). 
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Figure 2. p53 dependent and independent functions of ARF. Grey is for proteins whose activity 
or stability is positively regulated by ARF through p53-dependent mechanisms. p53- 
independent activity of ARF: Purple is for binding  partners induced to proteasome and 
ubiquitin- independent degradation by ARF. Green is for binding partners whose activity is 
blocked by ARF. Orange is for binding partners whose activity or stability is positively regulated 
by ARF. Red is for binding partners induced to proteasome and ubiquitin-dependent degradation 
by ARF. Blue is for binding partners which regulate ARF protein turnover. Adopted and 
modified from (91 Pollice,A. 2008). 
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I.3 C- terminal binding family proteins 
C-terminal binding proteins are well-characterized transcriptional co-repressors known to 
play important roles in cell proliferation, differentiation and survival. In humans and mice C-
terminal binding proteins consist primarily of two closely related proteins CtBP1 and CtBP2, 
which share 78% amino acid similarity (Bergman & Blaydes, 2006) . A third member of the 
family, CtBP3 has been identified as an N-terminal processed version of CtBP1, lacking the first 
20 amino acids, and plays an important role in the fragmentation of the golgi membranes at the 
beginning of mitosis (Bonazzi et al., 2005) In humans, these proteins are encoded by two genes 
Ctbp1 and Ctbp2 located on chromosomal regions 4p16 and 10q26.13, respectively.  
CtBP proteins were first identified as factors that bind the C-terminus of the adenoviral 
oncoprotein E1A at a consensus sequence PXDLS, and actively attenuate E1A’s oncogenic 
properties. Subsequently, functional studies revealed that CtBP’s function as transcriptional 
adaptors with both corepressor, and in some cases, coactivator functions (Bhambhani, Chang, 
Akey, & Cadigan, 2011). 
Although CtBP1 and CtBP2 are highly similar in structure, function, and expression, 
several differences have been identified so far. In mice, CtBP1 is expressed in embryos and 
adults and can relocate between the nucleus and the cytoplasm, but CtBP2 is primarily expressed 
in embryos and exclusively locates to the nucleus (Barroilhet et al., 2012). Moreover, in 
developing embryos CtBP1 and CtBP2 are not expressed ubiquitously in all t issues (Furusawa, 
Moribe, Kondoh, & Higashi, 1999). Like INK4A/ARF locus, the Ctbp2 locus encodes another 
protein termed RIBEYE using an alternative promoter. RIBEYE is a synaptic ribbon protein 
involved in facilitating the release of neurotransmitters by the continuous docking of synaptic 
vesicles on presynaptic ribbons (Schmitz, Konigstorfer, & Sudhof, 2000). RIBEYE lacks the first 
20 N-terminal amino acids of CtBP2, as a result of alternative splicing. Unlike the INK4A/ARF 
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locus, the expression of CtBP2/RIBEYE is in frame and tissue specific, occurring mainly in the 
retina (Chinnadurai, 2002).  
I.3.1 CtBP structure and function 
CtBP is a 48KDa phosphoprotein that has been evolutionary conserved among 
invertebrates and vertebrates whose activity has been shown to be regulated by stoichiometric 
variations in NADH/NAD ratio (Chen et al., 2009). As stated previously, CtBP protein possesses 
nuclear and cytoplasmic activities with the latter being more involved in maintaining vesicular 
membranes (Birts et al., 2010). Unlike ARF which possesses no known motifs, CtBP is a 
globular protein with peptide binding domain specific for PXDLS peptides (Nardini et al., 2006) 
responsible for its transcriptional activity (Figure 3), and a D2 hydroxy acid dehydrogenase 
domain responsible for NAD(H) binding and dimerization {{81 Nardini,M. 2006}}.  
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Figure 3. C- Terminal binding family protein functional domains (Chinnadurai, 2007) 
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The most accepted mechanism with which CtBP enforces repression is by recruiting 
DNA binding repressors through an HDAC dependent or independent manner. If HDACs are 
involved, the repression complex consists of either HDAC class I or class II and histone 
methyltransferases (HMTs) (Figure 4). In the absence of HDAC, CtBP recruits polycomb group 
complexes, or interacts with histone acetyltransferase co-activators (Bergman & Blaydes, 2006). 
In terms of developmental roles, ctbp1-null mice are runted but viable, whereas ctbp2 deficiency 
is embryonic lethal, with null embryos exhibiting multiple neurological and segmentation 
anomalies (Chinnadurai, 2003). 
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Figure4. Mechanism of CtBP1 transcriptional activities at the INK4A locus. Adopted and 
modified from (home.ccr.cancer.gov/inthejournals/gardner.asp). 
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I.3.2 CtBP possess oncogene like functions 
Previous studies on CtBP double null mouse embryonic fibroblasts, revealed 
hypersensitivity to apoptosis in response to several ectopic stimuli such as genotoxic stress, loss 
of cell contact inhibition (anoikis) and FasI ligand and UV irradiation (Paliwal et al., 2006). 
Gene expression profiling on CtBP-null MEFs, indicated upregulation of two sets of cancer-
related genes. The first set involved E-cadherin and cytokeratins, whereas the second included 
BH3-only genes (Noxa, Puma, Perp) (Bergman & Blaydes, 2006). These results indicate that 
CtBP is involved in cell survival and proliferation, and reintroduction of CtBP into CtBP1/2 
double knockout MEFs, attenuated the activity of pro-apoptotic genes, tumor suppressor genes 
and induced cell survival. This suggests that in cancer, CtBP functions as apoptosis antagonist 
and also in repressing tumor suppressor genes, such as BH3 proteins. As mentioned previously, 
CtBP possesses a dimerization domain intrinsic to the dehydrogenase homology domain that 
allows homodimerization or heterodimerization of CtBP family proteins upon NADH binding. 
Therefore, CtBP family proteins function as a dimer, and adequate levels of NADH are 
important in eliciting the dimerization/activation of CtBP.  
A major feature of solid tumors is poor vascularization due to rapid growth resulting in 
hypoxia. Hypoxia increases the levels of unbound NADH, which in turn activates the repressor 
activities of CtBP on the E-cadherin promoter allowing epithelial–mesenchymal transition, 
which is a normal process during embryogenesis, yet in cancer cells this is a step towards 
metastasis (Chinnadurai, 2009)(Q. Zhang et al., 2006). In a separate study, CtBP2 was shown to 
possess oncogene-like properties in ovarian cancer cells with high expression levels. siRNA 
mediated CtBP2 knockdown, resulted in a decrease in epithelial cancer cell proliferation, cell 
migration capacity and rendered ovarian cancer cells more responsive to HDAC 
inhibitors(Barroilhet et al., 2012). 
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I.3.3 Significance of ARF- CtBP interactions 
Several studies showed that CtBP is upregulated in many human cancers including 
breast, ovarian and colon cancers (Barroilhet et al., 2012). Increased CtBP activity in response to 
metabolic changes in the tumor microenvironment is accompanied by transcriptional repression 
of tumor suppressor genes (E-cadherin, PTEN, etc.) (Chinnadurai, 2009) resulting in EMT, and 
the repression of INK4A leading to senescence in primary human fibroblasts (Mroz, Baird, 
Michaud, & Rocco, 2008). As an apoptosis antagonist, CtBP mediates the repression of BH3 Bik 
gene by recruiting KLF-8 to the Bik promoter and this repression is abrogated by ARF 
overexpression, indicating that the INK4A/ARF locus is both a target and a regulator of CtBP 
(Kovi, Paliwal, Pande, & Grossman, 2010). 
Previous work in the Grossman laboratory, identified the carboxy-terminal domain of 
CtBP as a direct target of ARF and co-immunoprecipitation experiments identified the carboxyl 
terminal of CtBP2 as a platform for ARF binding, in particular amino acid residues 322-445, 
whereas ARF hydrophobic N-terminal amino acid residues 46-51 were necessary for that 
interaction. Introducing a point mutation in the conserved hydrophobic domain of ARF (L46D) 
abrogated the binding of ARF to CtBP without affecting ARF’s nucleolar localization. As a 
tumor suppressor, hARF expression mediated proteosomal degradation of CtBP without 
involvement of ectopic stress, whereas mARF proteasome mediated degradation of CtBP was 
evident only after UV irradiation (Paliwal et al., 2006). This work highlighted one mechanism of 
p53- independent tumor suppression of ARF, via its antagonism of CtBP-driven cell survival and 
migratory/invasive activities at least in cell line models (Kovi et al., 2010). 
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I.4 Cellular senescence: An overview 
Most human cells in vivo and in vitro possess an intrinsic property that limits their ability 
to divide indefinitely and lose homeostasis. This replication inhibitory phenomenon was 
described by Watson as the end replication problem since the replication machinery couldn’t 
include the terminals of a linear DNA with every round of DNA synthesis. Therefore, telomere 
shortening is a normal process that occurs in human cells with every cell division and has been 
linked to senescence and aging. On the contrary, mouse primary cells, do not show telomere 
shortening due to the presence of very long telomeres compared to human telomeres, and the 
ability of DNA polymerases to maintain those terminal sequences. What MEFs and human 
fibroblasts share in common is the ability of cells to establish senescence in culture after several 
passages  due to stress which is due in part to increasing levels of p19 and p16 (Espejel & 
Blasco, 2002). Loss of control over the cell cycle and continuous proliferation of human and 
mouse cells is a hallmark of cancer. Hence, senescence is a tumor suppressor mechanism that 
tends to maintain homeostasis by shifting cells towards a dormant state with metabolic activity. 
Cellular senescence is an irreversible form of the cell cycle arrest or quiescence. 
Depending on the context, cellular senescence can be one of two forms, replicative or premature. 
Replicative cellular senescence is induced by telomere shortening, which results in a DNA 
damage response once the telomeric secondary structures are lost with shortening . Depending on 
the severity of the DNA damage, cells can shift from transient arrest to senescence or apoptosis. 
Replicative senescence is mediated by the activation of ATM/ATR leading to functional 
upregulation of p53 and CDC25 activity (Kuilman, Michaloglou, Mooi, & Peeper, 2010).On the 
other hand,  cells entering premature senescence do not show attrition in their telomeres, yet they 
resemble replicative senescent cells in terms of high p16INK4A levels, large lysosomes and β-
galactosidase expression, flat shape and large size, and senescence associated heterochromatin 
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foci (SAHF) which silence critical pro-proliferative genes(Rodier & Campisi, 2011). Premature 
senescence can be induced by stress due to shock in culture, oncogene expression, or due to the 
loss of tumor suppressor genes (Kuilman et al., 2010).  
I.4.1 Oncogenic stress signals via H-rasV12 induces premature senescence in primary 
mouse embryonic fibroblasts 
The Ras family proteins N-Ras, K-Ras and H-Ras are small GTP binding proteins with 
GTPase catalytic activity. Ras oscillates from an active form when bound to GTP to an inactive 
form when bound to GDP and plays a crucial role in mediating growth signals to transcription 
factors that regulate the expression of proteins involved in cell cycle and differentiation. The Ras 
family proteins are encoded by a 46 kbp proto-oncogene  located on chromosome 12 in humans 
and chromosome 6 in mice and mutant forms are associated with more than 30 % of human 
cancers (McMahon & Woods, 2001). Ras family GTPases localize mainly to the cytoplasmic 
face of the phospholipid bilayer and are activated in response to signals that result in the 
phosphorylation of tyrosine kinases. Recent studies have shown that H-Ras can localize to the 
nucleus of non-transformed and primary mouse embryonic fibroblast, throughout the cell cycle 
(Contente, Yeh, & Friedman, 2011).  
Activated Ras primarily signals through the MAPK pathway, which is a cascade of 
transducing kinases that result in the activation of cyclin dependent kinases, and hence the 
upregulation of E2F transcription factors leading to cell cycle progression. In cancer, control 
over the H-Ras activity is lost due to amplification of Ras oncogene or constitutive activation of 
Ras due to a G12V point mutation, which renders H-Ras incapable of hydrolyzing GTP into 
GDP hence maintaining an active state. This high activity of H-Ras V12 is enough to 
immortalize most mammalian cells, yet induces premature senescence in primary cells (Kuilman 
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et al., 2010). H-Ras V12 mediated premature senescence is tissue specific and pathways involved 
are not favored equally in humans and mice. In humans, the most accepted pathway involved in 
oncogene induced senescence (OIS) involves the expression of p16 and the hypophosphorylation 
of Rb. It is worth mentioning that freshly prepared human embryonic fibroblasts are resistant to 
H-Ras V12 induced senescence because of their low or insignificant levels of p16 (Schauble et 
al., 2012). On the other hand, p19
Arf
 is the major sensor of OIS in MEF cells and primarily 
functions through the p53/p21 pathway, which is to date the most well characterized pathway in 
terms of inducing a permanent cell cycle arrest in PMEFs. This occurs through the p21-mediated 
inhibition through the inhibition of CDK2, maintaining Rb at a low phosphorylation state, and 
thus halting the cells at G1 phase. Although it is generally accepted that senescence is an 
irreversible form of cell dormancy, several studies showed that prematurely senescent cells were 
rescued upon the knockdown of tumor suppressor genes (Dirac & Bernards, 2003). For instance, 
human fibroblasts lacking p21 bypass H-RasV12 induced senescence and the disruption of either 
p16 or p53 was enough to evade the arrest in primary MEF cells (Serrano, Lin, McCurrach, 
Beach, & Lowe, 1997). 
I.4.2 Tumor suppression: Interplay between senescence, cell cycle arrest and apoptosis 
Senescence, cell cycle arrest, apoptosis and autophagy play a critical role in determining 
the fate of proliferating cells, and help maintain a state of equilibrium that once altered can lead 
to neoplasia. All of these mechanisms act as barriers to oncogenesis, and they are induced, in 
part, by DNA damaging agents such as UV irradiation, doxorubicin, and telomere shortening. At 
the molecular level, p53 appears to be involved in all of these mechanisms (Li et al., 2012), and 
what determines which mechanism stressed cells undergo vastly depends on the threshold of 
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DNA damage with cells exceeding a certain threshold of damage will be committed to either 
senescence, apoptosis or even autophagy(Kuilman et al., 2010).  
I.5 Aims of this study  
Mutations in proto-oncogenes, tumor suppressor genes and caretaker genes play an 
important role in carcinogenesis. Among the proteins that are encoded by proto-oncogenes is 
growth promoting signal proteins and their receptors, signal transduction proteins, transcription 
factors and anti-apoptotic proteins. In particular, mutant Ras protein (H-Ras V12) is an 
intracellular signal transduction protein that provides excessive growth promoting signals. 
Depending on the cell type, mutant H-Ras V12 activity has the tendency to induce cellular 
premature senescence, or immortalization/transformation. This solely depends on whether 
secondary mutations in tumor suppressor genes exist. The purpose of this thesis is to outline the 
functional significance of p19
Arf 
as a barrier for lymphoma development upon oncogenic stress 
and to explore the significance of ARF/CtBP2 interaction in vitro by using primary MEF cells as 
a model that could explain at least in part the biological outcome at the molecular level when 
ARF/CtBP2 binding is disrupted through the point mutation L46D in ARF. 
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Chapter II 
Materials and Methods 
 
 
 
II.1 Preparation of MEF cells 
Wild-type and ARF L46D/L46D mouse embryonic fibroblasts were explanted from 
E12.5-E13.5 embryos. Wild-type MEF cells were generated from embryos obtained from mating 
C57/BL6 wild-type mice. ARF L46D/L46D MEFs were established from embryos obtained from 
crossing C57/BL6 ARF+/ARF L46D heterozygote males and females. Pregnant females were 
sacrificed at day 12.5-13.5 following the standards set through IACUC. Uterine horns were 
rinsed in 70% alcohol then immersed in 1x PBS. Embryos were removed from the embryonic 
sac, placed in a sterile petri-dish and the head, red organs, tail and limbs were removed before 
mincing the trunk in 1 ml of 0.05% Trypsin–EDTA (Life technologies) using sterile surgical 
blade then pipetted into a 50ml conical tube and incubated at 37°C for 30 min and continuously 
pipetted in the hood every 5 min during the incubation period. Trypsin was inactivated by adding 
1 volume of pre-warmed MEF medium. Genomic DNA was digested by adding 2µl of DNase I 
per 1 volume of Trypsin/Medium and the mix was incubated for additional 15-20 min at 37°C. 
MEF cells were collected by centrifugation at 1500rpm for 5min.Gelatin pre-coated 10cm 
culture plates for 2 hours, were used to seed the cells at passage 0(P0) and the medium was 
replaced the second day. Primary MEF cells were kept at 37°C under 5% CO2 and passaged at a 
split ratio of 1:5 at 90% confluency. If not required immediately, MEF cells were frozen in 10% 
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DMSO in liquid nitrogen. MEF complete medium: DMEM (435ml), 10% FBS, PEN/Strep 
(5ml), L-Glutamine (5ml) and Non-essential amino acids (NEAA) (5ml). Embryos obtained 
upon crossing heterozygote males and females were genotyped by using a piece of the head for 
DNA extraction using QIAamp DNA mini Kit (Qiagen). Brain samples were incubated with 
lysis buffer (ALT) and proteinase-K at 55°C overnight. Genomic DNA was precipitated by 
ethanol on the spin column membrane and eluted by adding 200µl of Molecular Graded Water. 
A PCR reaction was performed using the following primers RL1, RL2 and RL3 (Table 4) 
followed by running the PCR products on 1.5% agarose gel for 30 min at 115V. Images were 
developed by exposing the gel to ultra violet light (UV) using alpha imager (Innotech). The 
expected product size is 250bp (Figure 5). 
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Figure 5. Representation of agarose gel electrophoresis for MEF genotyping. MEF cells were 
explanted from embryos upon mating C57/Bl6 ARF+/L46D female with C57/Bl6 ARF+/L46D 
male. Control 1 and control 2 determine whether the embryos are ARFL46D/L46D or 
ARF+/L46D mutants respectively. 
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    Table 4. Primers used in genotyping primary MEF cells 
Primer Sequence Properties 
RL1 5’CTCTGGCTTTCGTGAACATGGAT3’ Amplifies ARF 
L46D allele 
RL2 5’CGTGTGCAAAGTACTCCATCTCC3’ Reverse  primer 
common to wild-
type and ARF-L46D 
alleles 
RL3 5’CTCTGGCTTTCGTGAACATGTTG3’ Amplifies Wild-
type allele 
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II.2 Transient production of retroviral-based vectors for the transduction of MEF cells 
Three different replication-defective retroviral expression vector stocks were prepared 
through transient Transfection of HEK293T packaging cell lines. The day before transfection, 
5x10
5
 HEK293T cells (ATCC) were plated in 6cm culture plates in 5ml complete DMEM such 
that they reach 70% confluency on the day of transfection. Transfection of HEK293T cells was 
established through calcium-phosphate precipitation method. Prior to preparing the calcium 
phosphate precipitation mix, the medium was removed and replaced with 4.5ml incomplete 
medium, DMEM – P/S.  Three transfer vectors were used separately, pBABE-puro, pBABE-
HrasV12 and pBABE-GFP and simultaneously co-transfected with the packaging plasmid 
(pBABE- gag-pol) and the envelope plasmid (pMDG-VSV-g). A total of 10-15µg of DNA was 
added into a microcentrifuge tube, washed with water to a total volume of 225µl. The volume 
was adjusted to 250µl by adding 25µl of calcium chloride, and the mix was homogenized with 
finger tapping before adding it dropwise to 250µl of 2xHBS in a second microcentrifuge tube 
followed with vortexing at top speed for 3 seconds. The precipitation mix was incubated for 25 
min at room temperature in the culture hood before adding it dropwise to the 293T cells. The 
medium was replaced 16-18hr after transfection with complete medium, and viral stocks were 
harvested 48-72hr post-transfection. The viral supernatant was supplemented with 10µl of 
8mg/ml polybrene, and centrifuged at 1500rpm for 5 min in order to remove cellular debris. 
Excess viral stocks were frozen at -20°C. 
II.3 Cell culture 
Primary MEF cells including wild-type and ARF L46D/L46D MEFs were maintained in 
complete Dulbecco’s modified eagle’s medium containing 10% FBS, 1% 
penicillin/streptomycin, 1% L-glutamine and 1% non essential amino acids. ARF-null MEF 
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cells, previously obtained from UMass were propagated in culture for over 20 passages. ARF-
null, 3T3 MEFs and U2OS cell lines were maintained in complete DMEM medium. All cell lines 
were maintained in a humidified incubator under 5% CO2 at 37°C. 
II.4. DNA damage response 
All MEF cells were treated with 1µM of Doxorubicin Hydrochloride stock 10mM 
(Sigma). 4x10
5
 passage 1 (P1) Wild-type MEF cells and 2.5x10
5
 passage 3 (P3) ARF 
L46D/L46D MEF cell were seeded in 6cm culture plates such that they reached 70-80% 
confluency the second day.  The cells were treated for 2 hours, and then the medium was 
replaced again with complete DMEM. The cells were harvested at 1h, 2h, 4h, 8h and 24 hours 
post-pulse treatment for western blot analysis. Untreated cells (0h) were lysed for protein 
extraction during the 24h period. 
II.5. Retroviral infections 
Replication defective retroviral stocks stored at -20°C were thawed in a water bath a 
37°C and 1ml or 2ml of viral supernatant were added to cells growing in 6cm or 10cm culture 
plates respectively and left under 5% CO2 at 37°C. The viral cocktail was diluted 6-8 hours later 
with the appropriate volume of complete DMEM. On the second day, the cells were infected 
again for 6-8hours with the viral cocktail. For all cells lines, retroviral infections were done 
under extreme sanitizing conditions and once the viral cocktail was added, the plates were 
moved into a separate humidified incubator. For all assays, cells were infected for 48 hrs then 
selected with 2µg/ml of puromycin according to (Figure 6). NIH 3T3 cells were used as a control 
to determine the infection efficiency and were infected with retrovirus carrying green fluorescent 
protein transfer vector and selected with 2µg/ml of puromycin for 2 days and images were taken 
using AMG fluorescent microscope at a magnification of 40x. 
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Figure 6. Experimental design and reference time-frame in days 
 
 
II.6 Western blotting 
P1 wild-type, P1 ARFL46D/L46D and ARF-null MEF cells transiently infected with 
retroviruses carrying an Empty vector or H-RasV12 were seeded at 8x10
5
, 5x10
5
 and 4x10
5
 in 
10cm culture plates the day before transduction. Cells were infected for 2 days and selected for 2 
days in 2µg/ml puromycin. Cells were washed twice  in phosphate buffer saline (1x PBS), then 
lysed  in RIPA lysis buffer (50mM Tris-HCL, 150mM NaCl, 1% NP-40, 0.5% sodium 
deoxychelate, 0.1% sodium dodecyl sulfate SDS) supplemented with Complete mini EDTA free 
protease inhibitor cocktail (Roche) on ice. Wild-type and ARF L46D/L46D MEFs were lysed in 
a total volume of 300µl whereas ARF-null MEFs were lysed in 500µl of the lysis buffer cocktail 
for a total of 10-15 min on ice. The plates were scraped with a plastic scraper and crude lysates 
were collected in a microcentrifuge tube and vortexed at low speed and left on ice for additional 
5 minutes. The tubes were placed in a refrigerated centrifuge at 4°C and spun at a rotational 
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speed of 15000 rcf for 15 min. The supernatant was transferred into another microcentrifuge 
tubes and a bicinconinic acid (BCA) assay was performed in order to determine the lysate 
concentration. Into a 96well plate, 10 µl of each lysate was added in duplicates along with 
bovine serum albumin (BSA) standards of known concentrations, 0, 250, 500, 1000 and 2000 
µg/ml. The BCA solution was prepared by mixing 50 parts of solution A and 1 part of solution 
B. A total of 200µl was added into each well, mixed by pipetting and incubated at 37°C for 30 
min. The corresponding absorbances at 562nm were measured using Synergy H1 multi-mode 
microplate reader (Biotek). The concentrations of the lysates were calculated by plotting the 
concentrations of the BSA standards versus their measured absorbances. For cell cycle protein 
analysis of transduced cells, 20µg of total protein were loaded per well and proteins were 
resolved on a denaturing polyacrylamide gel NuPAGE (Bis-Tris 4-12%) for 35-50min at 200V 
in 1x NuPAGE-MES buffer. For DNA damage response and UV irradiation assays, 8-10µg of 
protein were loaded per well. The proteins were transferred to Immobilin polyvinylidine 
difluoride (PVDF) membranes 0.45µm (Millipore) which have been pre-activated in 100% 
methanol at 40V for 80min in 1X NuPAGE Transfer buffer (Life Technologies). The PVDF 
membranes were blocked in 0.2% blocking buffer (1volume of 1% casein, 4 volumes of 1x 
PBS), for 1hour and then incubated with primary antibodies at 4°C overnight while shaking. The 
membranes were washed with Tris-Buffered Saline 1x TBS-T (20% Tween-20) 5 times, 5 min 
each and incubated with the appropriate secondary antibody for 50 min at room temperature 
while shaking. A second wash with 1xTBS-T was performed 5x, 5 min each, and then the 
membranes were exposed to Odyssey Infra-red imager system (Licor). The following primary 
antibodies were used: Rabbit polyclonal anti-p53 antibody FL393 (sc6243) at 1:1000 dilution, 
rabbit polyclonal anti-p21 antibody M-19 (sc-471)at 1:1000, rabbit polyclonal anti-p16 antibody 
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M-156 (sc1207) at 1:1000 dilution, rabbit polyclonal anti- alpha actin antibody ( A2066) Sigma 
Aldrich at 1:3000 dilution, rabbit polyclonal anti-H-Ras antibody C-20 ( sc520) at 1:1000 
dilution, mouse monoclonal anti-MDM2 antibody 2A10 ( abcam) at 1:500 dilution, rabbit 
polyclonal anti-CDKN2A/p19ARF antibody ab80 ( abcam) at 1:1000, rabbit polyclonal anti-pRb 
(ser795) antibody(sc21875-R) at 1:1000 dilution, mouse monoclonal anti-CtBP2 antibody 
612044 (BD Transduction Laboratories) at 1:3000 dilution.  
II.7 Localization assay 
U2OS cells were seeded into BD Falcon four-well culture slides with polystyrene vessels 
at a density of 1x10
5
 cells in 1ml of complete medium per well and transfected using 
Lipofectamine 2000 transfection reagent with pcDNA3.1 plasmids encoding WT hARF, L50D 
hARF  and pcMV-Bam-HDM2. Plasmid DNA (µg) to Lipofectamine 2000 transfection reagent 
(µL) ratio was 1:2 and a total of 0.8 µg of plasmid DNA was used per well. Plasmid DNA and 
Lipofectamine 2000 were diluted separately  in 50µl of Opti-MEM- I reduced serum medium 
and incubated at room temperature for 5 min and then mixed to obtain a total volume of 100µl 
per transfection reaction. The combined volume was mixed gently and incubated for 20 min at 
room temperature. During the 20 min incubation period, the old growth medium was replaced 
with P/S free medium and then the cells were transfected by adding the 100µl complex dropwise 
to the culture vessels. Transfected U2OS cells were incubated under 5%CO2 at 37°C for 24 
hours and were not subjected to selection. U2OS cells were washed with 500µl, 1xPBS per well, 
then fixed with 4% paraformaldehyde (300µl/chamber) for 15min at room temperature. 
Chambers were washed again twice with 1xPBS before permeabilizing the membranes with 
0.5% Ttiton X (300µl/well) for 20 min at room temperature. Another wash with 1xPBS was 
performed as described before, and then 300µl of 5% goat serum blocking buffer were added per 
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chamber for 1h at room temperature (RT). U2OS cells were stained overnight while shaking with 
the following primary antibodies: mouse monoclonal anti- p14 ARF antibody DCS241 (sc-
53640), rabbit polyclonal anti-MDM2 antibody N-20 (sc813). Primary antibodies were diluted in 
(1% goat serum, 0.1% triton X) at a ratio of 1:100. The chambers were washed the second day 
and exposed for 50min without shaking and in the dark at RT to fluorescrein isothiocyanate 
(FITC) – conjugated goat anti-rabbit antibody (sc3839), and Texas red (TR)- conjugated goat 
anti-mouse antibody (sc362277) at 1:400 dilution. U2OS cells were washed again with 1xPBS 
and the chambers were physically detached from the glass slide before adding 10µl of the 
counter stain DAPI to the center of each well. The glass slides were covered with micro- 
coverslips (VWR INTERNATIONAL) and sealed with colorless nail polish. Images were taken 
using AMG fluorescent microscope at a magnification of 40x. 
II.8 Senescence- associated β-Galactosidase assay 
P1 Wild-type, P2 ARF L46D/L46D and ARF-null MEF cells were seeded into three 
separate 6-well plates in duplicates at the following cell densities: 5x10
4
, 7x10
4
 and 2x10
4
 
cells/well respectively. In each 6-well plate, 2 wells were left untreated, whereas the remaining 4 
wells were infected with retroviral cocktail containing either an Empty vector or H-Ras V12 and 
left for 6-8 hrs under 5% CO2 at 37°C. Complete medium was added after the primary incubation 
with the viral supernatant (sup) and the infection process was repeated the second day. Infected 
cells were selected with 2µg/ml puromycin for 3 days and the selection medium was replaced by 
complete medium on the last day of selection referred to as day 0. Primary MEF cells were 
stained on day3 (P4) and day 6 (p5) post selection using 5-bromo-4-chloro-indolyl-Beta-D-
galactopyranoside (X-gal) used as a substrate for β-galactosidase. MEF cells were washed twice 
in 1xPBS and fixed for 5 min in 2ml of fixing buffer (2% paraformaldehyde, 0.2% 
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glutaraldehyde in 1xPBS) per well and then washed again before adding 2ml of staining buffer. 
The staining buffer (20mg/ml X-gal in dimethyl formamide, 0.2M citric acid/ Na phosphate 
buffer pH6.0, 100mM potassium ferrocyanide, 100mM potassium ferricyanide, 5M sodium 
chloride, 1M Magnesium chloride and ddH2O) was prepared fresh prior to use.  The cells were 
incubated at 37°C overnight and washed the second day with 1xPBS. Images were taken using 
AMG light microscope at a magnification of 4x.  
II.9 UV irradiation 
Wild-type MEF cells P1, ARF L46D/L46D MEF cells P2 and ARF-null MEF cells were 
seeded into 6cm culture plates as described before and incubated overnight under 5%CO2 at 
37°C until they reached 70-80% confluency. The medium was removed and the plates were 
washed in 1xPBS and exposed to 254nm UV light using the stratalinker ( stratagene) at 
increasing amounts of energy: 0,5,10,20,30 J/m
2
 . Complete medium was added immediately 
after irradiation and the plates were left in the incubator for 6 hours post-treatment. Cells were 
washed and lysed on ice as described before. 
II.10 Statistical analysis 
For western blots, densitometric analysis was performed using Image J software. Protein 
levels were quantitated and normalized against actin loading control. For senescence-associated 
β-galactosidase assay, 100-200 cells were scored in at least 2 fields, and cells were counted 
manually using Image J software. The percentages of β-galactosidase positive cells were 
obtained by dividing the number of blue-colored cells by the total number of scored cells. 
Comparison between two groups was done using a two-sided Student’s t-test. P-value < 0.05 was 
considered statistically significant. All error bars represent the standard deviation of the mean 
from at least 2 independent biological replicates. 
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Chapter III 
Results 
 
 
 
I endeavored to test whether cells with the L46D mutation in the ARF gene exhibited 
normal or abnormal properties relative to known ARF or p53 biologic responses. In order to 
accomplish that, I assessed the outcome of the mutation under DNA damage stress, ultraviolet 
irradiation and oncogene overexpression through studying changes in the expression of cell cycle 
proteins in canonical pathways under different stress conditions. 
III.1 A conserved hydrophobic domain in p19Arf (37-51) is not required for the 
stabilization of p53 upon DNA damage stress.  
The tumor suppressor p53 is a key transcription factor involved in the transcription of 
apoptotic as well as cell cycle arrest genes and is mutated in more than 50% of human tumors. 
As mentioned previously, mice lacking p53 are embryonically viable but develop T-cell and B-
cell lymphomas as early as 20 weeks with 100% penetrance (Sharpless, 2005). Regardless of the 
molecular trigger, which can be oncogenic or DNA damage, p53 is stabilized indirectly by ARF 
or directly through phosphorylation events by ATM/ATR protein kinases (Kruse & Gu, 2009). 
Previous studies showed that p14
ARF
 is neither upregulated nor required for p53 stabilization 
upon genotoxic stress caused by topoisomerase inhibitor doxorubicin (anthracyclins), but might 
be involved in enhancing DNA damage signaling in response to DNA damage caused by 
alkylating agents such as cyclophosphamide(Eymin et al., 2006). In order to confirm these 
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results in MEF cells and define whether the point mutation L46D in ARF would lead to novel 
outcome compared to the wild-type ARF, MEF cells were seeded in 6 cm plates at a confluency 
of 40-70% depending on the cell line, and treated with 1μM doxorubicin for 2 hours. The drug-
containing medium was replaced after the 2 hour – treatment with complete medium, and the 
cells were lysed for protein extraction at different time points (See Materials and Methods).  The 
choice of the proposed time points and drug concentration was solely based on previous studies 
which showed that higher concentrations of doxorubicin or treatments extending for prolonged 
periods of time would result in increased apoptosis and/or transcriptional repression of target 
genes involved in the DNA damage response pathway (Attardi et al., 2000).  Western blot 
analysis clearly showed that the DNA damage response pathway was not influenced by the 
mutation in the conserved hydrophobic domain (L46D) of ARF, since p53 stabilization, p21 and 
MDM2 upregulation were equivalent in all cell lines (Figure 7).  
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             (A) 
 
               
 
              (B) 
 
                                    
Figure 7. Time course analysis of MDM2, p53 and p21 levels in doxorubicin-treated MEF cells. 
(A) P1 wild-type and (B) P3 ARF L46D/L46D MEFs were treated with 1µM doxorubicin for 
2hrs. Untreated cells (0h) were lysed for protein extraction during the 24h period. The blots were 
probed with actin as a loading control. Changes in MDM2, p53 and p21 expression levels were 
determined at the indicated time points by western blotting. 
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As expected these results confirmed that the role of ARF in DNA damage response is not 
essential, as abrogating CtBP2 binding to ARF through point mutation in the conserved 
hydrophobic domain did not lead to disruption of canonical DNA damage indicators, such as p53 
stabilization or p21 upregulation. 
 
III.2 Mutant p19ArfL46D maintains a nucleolar localization signal and fidelity to MDM2 
sequestration 
The most widely accepted dogma in defining the tumor suppressive functions of ARF is 
through its antagonistic activity against the murine double minute 2 E3 ligase (MDM2), whereby 
it exerts its effects in a p53-dependent pathway. Several studies have shown that endogenous 
MDM2 plays a role in ubiquitin mediated proteosomal degradation of p53 via its intrinsic E3 
catalytic ligase activity serving to constrain p53 levels (Honda, Tanaka, & Yasuda, 1997). ARF 
is predominantly a nucleolar protein that is kept at basal levels upon binding to the nucleolar 
protein nucleophosmin-B23. Increasing nuclear levels of ARF results in MDM2 sequestration to 
the nucleolus, leading to p53 stabilization as described previously (Weber, Taylor, Roussel, 
Sherr, & Bar-Sagi, 1999). ARF residues 1-14 and 26-37 are required for MDM2 binding, but 
amino acids 26-37 also bind B23, suggesting that B23 can compete with MDM2 for ARF 
association therefore inhibiting its function (Korgaonkar et al., 2005)(Korgaonkar et al., 2002). 
Interestingly, in some situations, p14 
ARF
 was found to exert its tumor suppressive functions by 
stabilizing p53 without relocating endogenous MDM2 from the nucleoplasm, suggesting that 
nucleolar homing of the ARF-MDM2 complex is not a necessity for the p53- dependent 
functions of ARF (Llanos, Clark, Rowe, & Peters, 2001). On the other hand, p53-independent 
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functions of ARF, which are still not fully characterized, were described previously where 
certain amino terminal deletion mutants in p19
Arf
 sequestered MDM2 without stabilizing p53, 
and others didn’t relocate MDM2 yet possessed growth inhibitory functions, suggesting that 
ARF exerts its effects in p53-dependent and independent pathways (Korgaonkar et al., 2002). To 
study the effects of the loss of ARF/CtBP2 interaction on the localization of mutant p14
ARFL50D
 
in humans (L46D in mice) and its ability to sequester MDM2 into the nucleolus, U2OS cells 
were transfected with pcDNA3.1-hARF, pcDNA3.1-L50D ARF, pcMV-Bam-HDM2 or co-
transfected with plasmid DNA expressing the wild-type or mutant p14
ARFL50D
 in combination 
with pcMV-Bam-HDM2.  The subnucleolar localization of ARF and its mutant was ascertained 
through immunofluorescent staining (Materials and methods) using antibodies against p14
ARF
, 
and HDM2. Wild-type ARF resided exclusively in the nucleolus and surprisingly did not co-
localize with HDM2 with the latter being predominantly distributed in the nucleoplasm (Figure 
8). On the other hand, mutant p14
ARFL50D
 showed a broader distribution, which is the norm for 
wild-type ARF based on previous supporting information, and co-localized with HDM2 in 
doubly transfected U2OS cells (Figure 8).  Co-localization of p14
ARFL50D
 with HDM2 was seen 
both in the nucleoplasm and inside the nucleolus suggesting that abrogating CtBP2 binding to 
ARF has no influence on the nucleolar localization signal that governs the shuttling of ARF into 
the nucleolus, nor-on the domain that governs MDM2 binding. More importantly, both p14-ARF 
and L50D-ARF stabilized p53 as inferred from lanes 1 and 3, since U2OS cells transfected with 
plasmids expressing only wt-ARF or p14
ARFL50D
 resulted in increased fluorescence activity upon 
staining for HDM2 when compared to lanes 7 and 8, which agrees with the negative feedback 
regulatory loop that defines the MDM2-p53 interaction (Moll & Petrenko, 2003)  
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Figure 8. Localization of HDM2 after induction of L50D-ARF. U2OS cells were transfected 
with wild-type hARF, L50D-ARF and HDM2 expression plasmids (1,3,6) and co-transfected 
with hARF and HDM2 or L50D-ARF and HDM2 expression plasmids (2,4,5) respectively. 
Twenty-four hours after transfection, cells were immunostained with mouse monoclonal anti- 
p14
ARF
 antibody and rabbit polyclonal anti-MDM2 antibody followed by detection with 
fluorescrein isothiocyanate (FITC) – conjugated goat anti-rabbit antibody, and Texas red (TR)- 
conjugated goat anti-mouse antibody. The merged image in (4) shows the co-localization of 
p14
ARFL50D
 and HDM2 in the nucleolus. 
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III.3 Disruption of ARF/CtBP2 interaction through point mutation in the ARF conserved 
hydrophobic domain results in rescue from UV induced proteosomal degradation of CtBP2 
It was reported in a previous study that the conserved hydrophobic domain (46-51) in 
p19
ARF
 co-immunoprecipitate with CtBP2, and interestingly over-expression of ARF or the 
depletion of CtBP2 rescued the expression of Bik in HCT116 p53-/- cells leading to p53-
independent apoptosis upon UV stress (Kovi et al., 2010), correlating with  ARF mediated 
proteosomal degradation of CtBP2 (Paliwal et al., 2006) . As expected, p19
ArfL46D
 over-
expression didn’t lead to Bik upregulation nor to apoptosis in HCT116 p53-/- cells (Kovi et al., 
2010) thus supporting the belief that CtBP2 effects on cell survival are through its repression of 
pro-apoptotic Bcl-2 homology domain 3 (BH3)-only genes, and ARF/CtBP2 interaction is 
necessary for ARF tumor suppressor activity in the absence of p53. In order to determine 
whether the loss of ARF/CtBP2 interaction would disrupt proteosomal degradation of CtBP2 
upon UV stress, which has been proposed to depend on ARF/CtBP2 interaction (Paliwal et al., 
2006), MEF cells from 4 different cell lines ( Wild-type, ARFL46D/L46D, ARF-null and p53-
null) were seeded into 6 cm plates and irradiated with ultra-violet light and cells were lysed 6 
hours later at a 70-80% confluency in order not to initiate contact inhibition signaling pathway 
that might lead to false positive result. The results shown in (Figure 9) confirm that the presence 
of full-length p19- ARF is required for CtBP2 destabilization after UV irradiation, since in ARF-
null MEF cells CtBP2 levels increased with increasing energies. It can also be inferred from 
these results that ARF can target CtBP2 to degradation in the absence of p53 since CtBP2 
decreased in p53-null MEFs with increasing energies similar to wild-type MEFs. As with ARF-
null cells, the levels of CtBP2 in ARF L46D/L46D MEF lysates increased with increasing 
energies (Figure 9), thus supporting the concept that under UV stress CtBP2 levels decrease 
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when ARF is present, and abrogating ARF/CtBP2 with a point mutation in the conserved 
hydrophobic domain rescued CtBP2 from proteosomal degradation. 
 
           (A)         (B) 
  
           
        (C)         (D) 
             
        
Figure 9. UV induced proteosomal degradation of CtBP2.  P1Wild-type (A), P2 ARF 
L46D/L46D (B), ARF-null (C) and p53-null (D) MEF cells were irradiated with increasing doses 
(0-30J/m
2
) of ultra-violet light (254nm). Changes in CtBP2 levels were determined by western 
blotting. CtBP2 levels were quantitated by densitometry and normalized to actin loading control.  
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III.4 The ARF conserved hydrophobic domain point mutation directs ARF functions in 
oncogene induced senescence 
Premature-senescence is a signaling program that is activated independently of telomere 
shortening (Espejel & Blasco, 2002) and triggered through mechanisms involving DNA damage, 
oxidative stress, ionizing radiation and oncogene activation(Sherr & DePinho, 2000). Early 
studies on premature senescence induction through mitogenic signaling involving the MAPK 
pathway have identified p53 and p16 as key regulators of the senescence program (Serrano et al., 
1997) (Lin et al., 1998). Unlike human fibroblasts, mouse embryonic fibroblasts favor the ARF-
p53-p21 axis in tumor suppression upon oncogenic stress as opposed to the p16-Rb-E2F pathway 
(Sharpless, Ramsey, Balasubramanian, Castrillon, & DePinho, 2004). Synthesis of p19
Arf
 is 
induced by overexpression of oncogenes such as c-myc, E1A, E2F1, and in particular, H-Ras 
V12 controls the expression of p19
Arf
 and p16 from the INK4A/ARF locus (Palmero, Pantoja, & 
Serrano, 1998). Regardless of the molecular trigger, premature senescence resembles replicative 
senescence in terms of flat cellular morphology with larger size compared to the non-senescent 
counterpart cells and increasing SA-Beta gal activity due to the increase in the size of the 
lysosomes (Dimri et al., 1995). In order to define the functionality of the senescence program in 
ARF L46D/L46D MEF cells upon oncogenic stress in search for answers that might explain 
lymphoma development in wild-type, ARF L46D/L46D and ARF-null MEF cells were 
retrovirally infected with and empty vector control or HRas-V12 and selected in 2µg/ml 
puromycin medium. P1 Wild-type and P2 ARF L46D/L46D MEF cells were fixed and stained 
on day3 and day6 (Figure 6) at passage numbers (P3, P4) and (P4, P5) respectively. The 
percentage of wild-type MEF cells expressing β-galactosidase as indicated by the blue colored 
cells on day6 (Figure 10- (A)) was higher in H-RasV12 expressing population (53%) as opposed 
to empty vector infected cells (29%)  (Figure 10-(B)).  On the contrary, ARF-null MEF cells 
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showed no detectable expression of β-galactosidase either upon H-RasV12 over-expression, or 
when infected with an empty vector control. These results were expected since ARF-null MEFs 
were immortalized through a 3T9 cell immortalization assay (data not shown). Interestingly, the 
pool of ARF L46D/L46D MEF cells which expressed β-galactosidase was significantly lower 
than those in wild-type both on day 3 ( 7%) and day 6 (10%) (Figure 10-(B)), suggesting that 
disrupting the conserved hydrophobic domain responsible for ARF/CtBP2 interaction results in 
abrogation of the senescence program mediated by full-length ARF. 
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(A) 
         
        (B)                          
                                       
 
                          
Figure 10. Oncogene induced senescence upon ectopic expression of H-RasV12. P1wild-type, P2 
ARFL46D/L46D and ARF-null MEF cells were transduced with retroviruses expressing an 
empty vector or H-RasV12. (A) Acidic Beta-galactosidase staining performed on day 3 and day 
6, (B) Bar diagram showing the percentage of β-galactosidase positive cells in wild-type and 
ARF L46D/L46D MEF cells. Error bars are SE. 
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III.5 H-RasV12 mediated induction of p21 is compromised in MEF cells harboring a point 
mutation in the conserved hydrophobic domain (37-51) in ARF. 
In order to study the effects of disrupting ARF/CtBP2 binding on the expression of key 
senescence-associated cell cycle regulators, wild-type, and ARFL46D/L46D and ARF-null MEF 
cells were seeded in 10cm plates and were infected with retroviral cocktails expressing H-
RasV12 or an empty vector control (Materials and Methods), and lysates were analyzed for p19-
ARF, p53, p21, MDM2, p16, CtBP2 and phospho-Rb levels. Consistent with previous studies, 
H-RasV12 led to an increase in p19
Arf
, MDM2, p53 and p21 in wild-type MEFs supporting the 
idea that in normal cells, stabilization of p53 leads to cell cycle arrest by inducing p21 expression 
(Figure 11). It was not unexpected to see CtBP2 levels not change in wild-type cells expressing 
H-RasV12, considering that though p19
Arf
 was upregulated, there was no concomitant UV or 
other oxidative stress (Paliwal et al., 2006). ARF-null MEF expressing H-RasV12 surprisingly 
showed increasing levels of p53 and p21, although no p19
Arf
 was detected. Increasing p53 
stability could be partially explained by H-Ras V12 induced chromosomal instability leading to 
accumulation and phosphorylation of p53 (Woo & Poon, 2004). Failure to detect p16 expression 
in ARF-null MEFs expressing H-RasV12 or control empty vector was not expected (Figure11), 
since previous studies showed that p16 is expressed in ARF deficient cells (Kamijo et al., 1997). 
One explanation to the absence of p16 in ARF-null cells could be attributed to chromosomal 
instability due to continuous passaging in culture. Although no detectable levels of p16 were 
seen, using ser-795 phospho-specific antibody against Rb showed that hyperphosphorylated Rb 
was only and equally detected in ARF-null cells infected with an empty vector or H-RasV12, 
suggesting that in the absence of ARF and p16, CDK4 was therefore invariably functional 
regardless of H-RasV12 activity, correlating with high proliferation rate ( data not shown).  
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Unlike ARF-null cells, ARF L46D/L46D MEF cells maintained a functional p16-Rb axis 
similar to wild-type MEFs, with upregulation of p16 and low phospho-Rb levels (Figure11). 
Paradoxically, H-RasV12 overexpression led to p53 stabilization in ARFL46D/L46D MEFs 
similarly to wild-type cells, significant p21 expression was not observed as compared to wild-
type cells (Figure 11), suggesting that the ARF-p53 pathway is indeed defective in ARF 
L46D/L46D MEFs, and this correlates with a defect in oncogene induced senescence.  
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Figure 11. Ectopic expression of H-RasV12 does not induce p21 expression in ARFL46D/L46D 
MEF cells. P1wild-type, P1 ARFL46D/L46D and ARF-null MEFs were retrovirally transduced 
with an empty vector or H-RasV12 for 2 days and harvested on day 2 post-selection and lysates 
were analyzed by western blotting of the following proteins: MDM2, p53, p21, p19, p16, ppRb 
(ser795), and CtBP2.  
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Chapter IV 
Discussion and Future Directions 
 
 
 
Cellular aging (replicative senescence) and programmed cell death (apoptosis) are two 
normal biological processes that are intended to maintain homeostasis in mammals, and 
deregulation of either one may lead to several neurodegenerative disorders, diabetes and cancer. 
Hence, senescence and apoptosis act as safe-guard mechanisms, and failure to establish either 
process imposes increasing risks in cancer formation. Most anti-cancer therapeutics aim at 
triggering tumor cell death, but apoptosis-based therapeutic methods are limited by high toxicity 
and lack of selectivity between normal and tumor cells. In addition, many cancer cells are 
refractory to chemotherapeutic agents since available drugs primarily function by inducing cell 
death through apoptosis in fast dividing cells which can include pluripotent normal cells in the 
gastro-intestinal tract or bone marrow. Moreover, cancer stem-like cells have been found 
irresponsive to these chemical agents and radiotherapy, leading to disease progression despite 
therapeutic intervention (Morrison et al., 2011). Therefore, exploring senescence as an 
alternative method in treating cancer lead to new avenues of therapy to suppress chemo- and 
radio-resistant cancer stem-like cells that are believed to underlie therapy failures and relapse 
(Cahu, Bustany, & Sola, 2012). 
The INK4A/ARF locus acts as a sensor of stress signals and expression of p16 and p19
Arf
 
in mice has been linked to tissue culture stress, oxidative stress and oncogene activation. 
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Supporting evidence suggests that in mouse embryonic fibroblasts, the loss of key downstream 
effector of p19
Arf
, p53, results in cellular immortalization as opposed to the loss of pRb, the 
downstream target of p16 (Peeper, Dannenberg, Douma, te Riele, & Bernards, 2001). Moreover, 
the loss of all the Rb family proteins (pRb, p107, p130) would result in immortalization 
suggesting that the Rb family proteins act both upstream and downstream of the ARF-p53 
axis(Sage et al., 2000). The extent to which the ARF-p53 pathway contributes to H-RasV12 
induced premature senescence in MEF cells independent of p16 is relative, since CDK4-null 
MEFs were resistant to transformation in response to H-Ras V12 activation and p53 
inhibition.(Zou et al., 2002). Interestingly, the same study showed that CDK4-null MEFs showed 
increasing levels of p21 upon H-RasV12 activation and p53 inhibition by dominant negative p53 
(DNp53), and cells underwent senescence. This suggests that increasing H-RasV12 activity and 
depending on the cell context, would lead to premature senescence correlating with increase in 
the levels and stability of p21, even when the ARF-p53 axis is lost. 
The major purpose of this study was to test the functions relevant to regulation of stress 
responses of the tumor suppressor ARF upon disrupting its binding to CtBP2 through a point 
mutation (L46D) in the conserved hydrophobic domain (37-51). We showed that p19
ArfL46D
 did 
not disrupt p53 stabilization in MEF cells treated with the DNA damaging agent doxorubicin, 
nor did doxorubicin induce the transcriptional activation of ARF (data not shown). Using 
immunofluorescent techniques, we confirmed that the L46D mutation in the conserved 
hydrophobic domain did not interfere with the nucleolar localization sequence. Most 
importantly, ARF L46D/L46D maintained a functional MDM2 binding sequence as determined 
by the co-localization of mutant ARF and MDM2 in accordance with previous biochemical data 
(Paliwal et al., 2006). Previous work done in the Grossman Lab at UMass showed that CtBP2 is 
 
 
53 
 
targeted for proteosomal degradation upon UV irradiation in an ARF-dependent manner. 
Although it is not clear how p19
ARF
 destabilizes CtBP2 in conditions of UV stress, ARF seems to 
mediate the delivery of ubiquitinated CtBP2 to the proteosome. Our results indicate that 
abrogating ARF/CtBP2 binding results in CtBP2 stabilization similar to what was shown 
previously in ARF null cells. Lastly, we assessed the behavior of MEF cells bearing the L46D 
mutation in response to oncogenic stress. Our data indicates that MEF cells with mutant ARF are 
not responsive to H-RasV12 induced senescence, and we have identified that p21 deficiency is 
most likely the underlying molecular defect which is promoting cell survival in ARFL46D/L46D 
MEF cells. Taken together, our results explain a possible molecular basis for lymphoma 
development in ARFL46D/L46D mice, as due to the loss of normal ARF-mediated oncogene 
induced senescence and p21 induction (Figure 11). Whether the defect impinges on a p53 
dependent or independent pathway for ARF-induced senescence was not directly addressed in 
this study, though the involvement of p21 suggests a p53 dependent pathway. Indeed, a more in-
depth testing on the underlying causes for p21 low expression levels is required, since these 
results were observed once from a single population of ARFL46D/L46D MEF cells and 
therefore maybe subject to variability (Appendix-I). 
The ARFL46D/L46D knock-in mice were generated in order to characterize the 
physiologic significance of the interaction between ARF and CtBP2. Mice homozygous for the 
mutation in the conserved hydrophobic region of ARF showed a similar tumor profile to that 
seen in ARF-null mice, but with a longer mean tumor latency, suggesting that ARF L46D/L46D 
is contributing to tumor suppression possibly due to a combination of p53–dependent and 
independent mechanisms. In this study, we used mouse embryonic fibroblasts as a model to test 
for the outcomes of disrupting ARF/CtBP2 binding in cases of genotoxic and oncogenic stress. 
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Since all tumors that developed were lymphomas, then it is reasonable in the future, to study the 
effects of the L46D mutation in splenocytes, thymocytes or lymphoma cells under the same 
stress conditions used on MEF cells. Moreover, MEF cells don’t share the same lineage with 
lymphocytes, which might account for changes in the identity of the mediators functioning in the 
senescence program. There is another advantage in shifting the study to lymphocytes. As 
discussed previously, no detectable changes in CtBP2 levels were seen in wild-type MEF cells 
expressing active H-Ras. Indeed, CtBP2 sequestration by ARF alone is not necessarily a signal 
for CtBP2 proteosomal degradation. However, since primary MEF cells are explanted from 
developing embryos, it is expected that CtBP2 levels are originally high, as CtBP2 has been 
associated with fine tuning the transcriptional response in development (Y. W. Zhang & Arnosti, 
2011).  
Gain of function mutations lead to abnormal functions and are dominant over the wild-
type gene products. Based on that, it is critical to test whether the substitution of the hydrophobic 
Leucine with a hydrophilic aspartic acid in the L46D residue would result in a mutant p19
Arf 
with 
novel properties. Accordingly, through immunoprecipitation and localization assays, we can 
further assess whether mutant ARF is sequestering p53 in conditions of oncogenic stress. Further 
testing on whether ARFL46D/L46D MEF cells behave similarly to ARF-null MEFs in regard to 
evasion of apoptosis upon UV irradiation would confirm our hypothesis and suggestion 
regarding CtBP2 stabilization when not sequestered by ARF. 
Although SA-B-gal is one of the most widely used markers for senescence, there is no 
evidence that β-galactosidase itself is involved in modulating the senescence program. Further 
studies showed that it is not a legitimate but rather a surrogate marker for increased lysosomal 
activity and size, features common in aging cells (Lee et al., 2006). Based on this, using other 
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markers such as γH2AX, Ki67, PAI-1 in combination with X-gal in MEFs or lymphocytes would 
be a better approach for detecting senescence in response to oncogenic stress. Regardless of the 
drawback, our results indicate that a deterioration in the senescence program occurred in 
ARFL46D/L46D MEF cells. In order to further expand on the deficits in p21, chromatin 
immunoprecipitation (ChIP) study on the p21 promoter region and using antibodies specific for 
p53 (to ensure that there is no impact on p53 localization at the promoter) and CtBP2 (a known 
repressor of p21) (Madison & Lundblad, 2010) , would significantly discern key differences seen 
among wild-type and ARFL46D/L46D MEF cells. We hypothesize that CtBP2 is more 
abundantly occupying the promoter region of p21 and therefore antagonizing p53 mediated 
transcriptional initiation in cells where ARF cannot target CtBP for degradation. Real-time PCR 
preliminary results (data not shown) indicated low levels of p21 mRNA in ARFL46D/L46D 
MEF cells compared to the wild-type when infected with empty vector and H-RasV12, in 
accordance with the western blot results (Figure11).  If CtBP2 was not found associating with 
p21 promoter, an alternative hypothesis is that oncogenic MDM2 is functioning as a negative 
regulator on p21 independent of p53. Again, ChIP of the p21 promoter region with MDM2 
antibody followed by real-time PCR on the precipitated fragments from the different cell line is a 
good start point. Finally, since MTOB has proven efficiency against tumor cells, it is critical to 
test the drug in vivo once lymphoma is detected and at later stages in ARF-null and ARF 
L46D/L46D mice. 
In conclusion, our data suggests that escape from senescence is a mechanism with which 
ARFL46D/L46D MEF cells are selected for survival and continuous proliferation, and a 
potential reason for lymphoma development in mice bearing the L46D mutation on both ARF 
alleles. 
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Appendix-I 
 
p21 expression may be subject to variability among ARFL46D/L46D MEF cells 
      (A)       
  
               (B) 
 
Figure A1. Ectopic expression of H-RasV12 induces p21 expression but not senescence in ARF 
L46D/L46D MEF cells of a particular lineage. P1 wild-type MEFs, P1 ARFL46D/L46D MEFs 
obtained from mating a homozygous male (ARFL46D/L46D) with a heterozygous female 
(ARF+/ARFL46D) and ARF null MEFs were retrovirally transduced with an empty vector or 
H-RasV12 as described before. (A) Western blot analysis on MDM2, p53 and p21. (B) Bar 
diagram showing the percentage of β-galactosidase positive cells in wild-type and 
ARFL46D/L46D MEF cells. Error bars are SE. 
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